Astellas Announces U.S. FDA Grants Priority Review for Zolbetuximab Biologics License Application
/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA)...